Laserfiche WebLink
13 <br />including, but not limited to approaches modeled on the Arrestee Drug <br />Abuse Monitoring (“ADAM”) system. <br />8.Qualitative and quantitative research regarding public health risks and <br />harm reduction opportunities within illicit drug markets, including surveys <br />of market participants who sell or distribute illicit opioids. <br />9.Geospatial analysis of access barriers to MOUD and their association with <br />treatment engagement and treatment outcomes. <br />M.POST-MORTEM <br />1.Toxicology tests for the range of opioids, including synthetic opioids, seen in <br />overdose deaths as well as newly evolving synthetic opioids infiltrating the drug <br />supply. <br />2.Toxicology method development and method validation for the range of synthetic <br />opioids observed now and in the future, including the cost of installation, <br />maintenance, repairs and training of capital equipment. <br />3.Autopsies in cases of overdose deaths resulting from opioids and synthetic <br />opioids. <br />4.Additional storage space/facilities for bodies directly related to opioid or synthetic <br />opioid related deaths. <br />5.Comprehensive death investigations for individuals where a death is caused by or <br />suspected to have been caused by an opioid or synthetic opioid overdose, whether <br />intentional or accidental (overdose fatality reviews). <br />6.Indigent burial for unclaimed remains resulting from overdose deaths. <br />7.Navigation-to-care services for individuals with opioid use disorder who are <br />encountered by the medical examiner’s office as either family and/or social <br />network members of decedents dying of opioid overdose. <br />8.Epidemiologic data management and reporting to public health and public safety <br />stakeholders regarding opioid overdose fatalities. <br />DocuSign Envelope ID: 040056EC-0D41-4D98-9C65-E01AE876A6AB